pazopanib

Type: Keyphrase
Name: pazopanib
First reported Jul 25 2014 - Updated Jul 26 2014 - 1 reports

Nexavar fails late-stage breast cancer trial

Efforts by Bayer and Amgen subsidiary Onyx to expand the indications of their cancer drug Nexavar into breast cancer have hit the buffers.The results of a phase III trial called RESILIENCE showed that Nexavar (sorafenib) given in combination with capecitabine ... [Published PMLive - Jul 25 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Drugs to Avoid in Patients on Tyrosine Kinase Inhibitors

With the rapid and widespread uptake of tyrosine kinase inhibitors (TKIs) in oncology over the past several years, serious drug–drug interactions are an "increasing risk," according a new report.To guarantee the safe use of TKIs, "a drugs review for each ... [Published Diabetes Care - Jul 25 2014]
First reported Jul 24 2014 - Updated Jul 25 2014 - 2 reports

Forum Post: RE: Pazopanib trials

friends who have experience of kidney cancer and friendsPazopanib trialsPosted by pink sugar on24 Jul 2014 11:36 PMHas anyone been on the Pazapanib trial to see if it will stop RCC coming back?I finished taking Pazopanib last September and my last scan ... [Published Macmillan Cancer Support - Jul 25 2014]
First reported Jul 23 2014 - Updated Jul 24 2014 - 1 reports

GSK shares sink as sales decline again

GlaxoSmithKline has posted another disappointing set of financials which show that second-quarter sales fell 13%, while core operating profit sank 25% to £1.41 billion.Group sales came in at £5.56 billion, while pharmaceutical and vaccines turnover was ... [Published Pharma Times - Jul 23 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 2 reports

The Texas Medical Board vs. Stanislaw Burzynski, Round Infinity [Respectful Insolence]

There’s a point I feel that I have have to make briefly as I begin this post. Basically, this might look familiar, but given that I was at TAM Wednesday through Sunday, I didn’t have time to produce two separate posts, and this is important enough ... [Published ScienceBlogs : Combined Feed - Jul 14 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 1 reports

Abington Memorial Hospital Details Findings in Gynecology (A phase II evaluation of pazopanib in the treatment of recurrent or persistent...

Abington Memorial Hospital Details Findings in Gynecology (A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group study)By a News Reporter-Staff News Editor at Clinical ... [Published Pharmacy Choice - Jul 14 2014]
First reported Jun 28 2014 - Updated Jun 28 2014 - 1 reports

Ask Fuzzy: Why does chemotherapy make hair fall out?

Question: Why does chemotherapy cause hair to fall out? Can it make it go grey?Chemotherapy used in cancer treatment affects rapidly dividing cells, which includes the tumour cells it is aimed at treating but also normal fast-dividing cells such as hair ... [Published Canberra Times - Jun 28 2014]
First reported Jun 25 2014 - Updated Jun 25 2014 - 1 reports

Facilitating Partial Nephrectomy with Pre-Operative Pazopanib

| GRACEWhen a patient has a localized renal mass, a partial nephrectomy is the desired surgical approach because it preserves renal function. Depending on the tumor size and location, a partial nephrectomy is not always possible. In these cases, pazopanib, ... [Published BioPortfolio - Jun 25 2014]
First reported Jun 20 2014 - Updated Jun 20 2014 - 1 reports

Another Option for Late-Stage Medullary Thyroid Cancer?

A Multicenter Phase 2 Trial of Pazopanib in Metastatic and Progressive Medullary Thyroid Carcinoma: MC057HBible KC, Suman VJ, Molina JR, et al, for the Endocrine Malignancies Disease Oriented Group, Mayo Clinic Cancer Center, and the Mayo Phase 2 Con ... [Published American Journal of Public Health - Jun 20 2014]
First reported Jun 19 2014 - Updated Jun 19 2014 - 1 reports

Nivolumab Appears 'Promising' in RCC

Nicholas J. Vogelzang, MD: I'm Nick Vogelzang, Professor of Medicine, University of Nevada School of Medicine and Vice Chair of the Southwest Oncology Group Genitourinary Committee. My work is in oncology research at the Comprehensive Cancer Centers in ... [Published Diabetes Care - Jun 19 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 2 reports

EMA App Withdrawn for GSK Ovarian Cancer Drug

GlaxoSmithKline plc announced that it has withdrawn its application to the European Medicines Agency (EMA) for a variation to the Marketing Authorization for Votrient (pazopanib). Related Biotechnology, Pharmaceutical and Healthcare NewsOriginal Article: ... [Published BioPortfolio - Apr 02 2014]
First reported Mar 31 2014 - Updated Apr 01 2014 - 4 reports

Votrient's extended licence application ditched

GlaxoSmithKline admits it is ‘disappointed’ after abandoning its attempt to extend kidney cancer drug Votrient’s licence to take in ovarian cancer.The company has withdrawn an application to the European Medicines Agency for a variation to the marketing ... [Published BioPortfolio - Apr 01 2014]

Quotes

"In case of a suspected interaction, and if pharmacokinetic data are not available, physicians and pharmacists should balance the available evidence, if possible, extrapolate available pharmacokinetic data for an individual patient, and monitor closely for toxic effects and response" they conclude
...94 shortly after the company reported disappointing second-quarter 2014 financial results, and chief executive Sir Andrew Witty admitted that "it is now unlikely that we will deliver sales growth this year."
The lacklustre performance led to a revised full-year forecast by GSK and a prediction that core earnings per share would be "broadly similar to 2013”, compared with a previous prediction of 4%-8%."
...According to news reporting originating from Abington, Pennsylvania, by NewsRx correspondents, research stated, "Carcinosarcomas of the female genital tract, also called malignant mixed mullerian tumors, are aggressive biphasic tumors. Second-line treatment options in the recurrent/persistent setting have yielded marginal responses."

More Content

All (44) | News (35) | Reports (0) | Blogs (7) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Forum Post: Dad with terminal cancer and a mum ... [Published Macmillan Cancer Support - Jul 26 2014]
Drugs to Avoid in Patients on Tyrosine Kinase I... [Published Diabetes Care - Jul 25 2014]
Nexavar fails late-stage breast cancer trial [Published PMLive - Jul 25 2014]
Forum Post: RE: Pazopanib trials [Published Macmillan Cancer Support - Jul 25 2014]
Forum Post: Pazopanib trials [Published Macmillan Cancer Support - Jul 24 2014]
GlaxoSmithKline slashes forecast as 2nd-qtr sal... [Published Pharma Letter - Jul 24 2014]
GSK shares sink as sales decline again [Published Pharma Times - Jul 23 2014]
Forum Post: RE: secondary renal cancer [Published Macmillan Cancer Support - Jul 22 2014]
Forum Post: secondary renal cancer [Published Macmillan Cancer Support - Jul 21 2014]
Managing Radioactive Iodine-Refractory Thyroid ... [Published General Medicine eJournal - Jul 15 2014]
The Texas Medical Board vs. Stanislaw Burzynski... [Published ScienceBlogs : Combined Feed - Jul 14 2014]
Abington Memorial Hospital Details Findings in ... [Published Pharmacy Choice - Jul 14 2014]
The Texas Medical Board vs. Stanislaw Burzynski... [Published Science-Based Medicine - Jul 14 2014]
Forum Post: My husband has kidney cancer. [Published Macmillan Cancer Support - Jul 09 2014]
18F-FGD-PET measures predict mRCC TKI response [Published News-Medical.Net - Jun 30 2014]
Ask Fuzzy: Why does chemotherapy make hair fall... [Published Canberra Times - Jun 28 2014]
Active surveillance for metastatic or recurrent... [Published UroToday - Jun 27 2014]
18F-FGD-PET measures predict mRCC TKI response [Published MedWire News - Jun 27 2014]
Facilitating Partial Nephrectomy with Pre-Opera... [Published BioPortfolio - Jun 25 2014]
Another Option for Late-Stage Medullary Thyroid... [Published American Journal of Public Health - Jun 20 2014]
Nivolumab Appears 'Promising' in RCC [Published Diabetes Care - Jun 19 2014]
Old member, new name? [Published HealthBoards - Jun 05 2014]
Axium Healthcare Pharmacy joins GSK oncology ne... [Published PharmaBiz - May 10 2014]
GSK Launches Sri Lanka's First Targeted Treatme... [Published BioPortfolio - May 06 2014]
Overall Survival in Renal-Cell Carcinoma with P... [Published The New England Journal of Medicine: Hematology ... - May 01 2014]
Withdrawn application: Votrient, pazopanib, Pos... [Published Withdrawn Application - Apr 25 2014]
Kidney cancer In crossover study patients and p... [Published BioPortfolio - Apr 16 2014]
EMA App Withdrawn for GSK Ovarian Cancer Drug [Published BioPortfolio - Apr 02 2014]
Results from phase III patient preference study... [Published News from Kidney Cancer Association - Apr 02 2014]
Votrient's extended licence application ditched [Published BioPortfolio - Apr 01 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
The Texas Medical Board vs. Stanislaw Burzynski... [Published ScienceBlogs : Combined Feed - Jul 14 2014]
There’s a point I feel that I have have to make briefly as I begin this post. Basically, this might look familiar, but given that I was at TAM Wednesday through Sunday, I didn’t have time to produce two separate posts, and this is important enough ...
The Texas Medical Board vs. Stanislaw Burzynski... [Published Science-Based Medicine - Jul 14 2014]
As I begin this post, I’m no a miserably crowded, hot, stinky flight winging my way home from TAM . This puts me in the perfect mood to write about my bête noire to conquer all bêtes noires, namely Stanislaw Burzynski, the Polish expat doctor who ...
Old member, new name? [Published HealthBoards - Jun 05 2014]
When I was diagnosed with follicular ThyCa back in late 2005 I posted under my first and last name but after several years of inactivity I came back and found that Admin had changed my login to my first name along with a number. After several years more ...
Overall Survival in Renal-Cell Carcinoma with P... [Published The New England Journal of Medicine: Hematology ... - May 01 2014]
To the Editor: In the August 22 issue, we reported on a phase 3 trial showing the noninferiority, with respect to progression-free survival, of pazopanib versus sunitinib as first-line treatment for clear-cell, metastatic renal-cell carcinoma, as assessed ...
Withdrawn application: Votrient, pazopanib, Pos... [Published Withdrawn Application - Apr 25 2014]
1 2

Press Releases

sort by: Date | Relevance
TRACON Pharmaceuticals Initiates Phase 1b Study... [Published GlobeNewswire: Acquisitions News - Feb 03 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.